Ratings Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.6962 USD +0.19% Intraday chart for Forte Biosciences, Inc. +0.90% -15.27%

Summary

  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-15.27% 25.34M -
D+
+2.73% 108B
B+
+9.59% 103B
B+
+6.58% 23.48B
B
-12.59% 21.93B
B+
-3.29% 19.68B
A-
-35.36% 18.37B
A-
-13.29% 16.33B
B
+4.68% 13.72B
C+
+34.25% 12.15B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
-
Profitability
-
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
-
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes